Posted by: ctraderd | July 23, 2012

AMRN News Coming Soon

Amarin Corporation PLC (AMRN) has a drug called AMR101 which is used to treat high triglyceride levels. The drug has received approval on its NDA and is currently under evaluation by the FDA with a PDUFA date set on Thursday, July 26, the same day Horizon Pharmaceuticals (HZNP) has their PDUFA for Lodotra. If AMRN’s drug is approved, their stock price will likely shoot up and then get run-down.

Amarin is developing AMR101 for the potential treatment of patients with very high triglyceride levels and high triglyceride levels, or hypertriglyceridemia. Triglycerides are fats in the blood. Amarin’s cardiovascular strategy leverages our extensive knowledge and experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids in cardiovascular disease.



Disclosure: I am long AMRN and hold Calls.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s


%d bloggers like this: